On March 20, 2018 -X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, reported that the company will participate in two upcoming investor conferences (Press release, , 20 20, 2018, View Source [SID1234524907]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

X4 Pharmaceuticals will participate in two conferences: BioCentury Future Leaders in the Biotech Industry Conf 3/23 and Needham Healthcare Conf 3/28.

Tweet this
On Friday, March 23, at 3:00 p.m. ET, Paula Ragan, PhD, President and Chief Executive Officer, will present a company overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York, NY. A breakout session will follow the presentation at 3:30 p.m.

On Wednesday, March 28, at 11:00 a.m ET, Dr. Ragan will make a presentation on X4 at Needham & Company’s 17thAnnual Healthcare Conference at the Westin Grand Central in New York, NY.